journal article May 30, 2023

High-level in vitro resistance to gentamicin acquired in a stepwise manner in Neisseria gonorrhoeae

View at Publisher Save 10.1093/jac/dkad168
Abstract
Abstract

Objectives
Gentamicin is used in several alternative treatments for gonorrhoea. Verified clinical Neisseria gonorrhoeae isolates with gentamicin resistance are mainly lacking and understanding the mechanisms for gonococcal gentamicin resistance is imperative. We selected gentamicin resistance in gonococci in vitro, identified the novel gentamicin-resistance mutations, and examined the biofitness of a high-level gentamicin-resistant mutant.


Methods
Low- and high-level gentamicin resistance was selected in WHO X (gentamicin MIC = 4 mg/L) on gentamicin-gradient agar plates. Selected mutants were whole-genome sequenced. Potential gentamicin-resistance fusA mutations were transformed into WT strains to verify their impact on gentamicin MICs. The biofitness of high-level gentamicin-resistant mutants was examined using a competitive assay in a hollow-fibre infection model.


Results
WHO X mutants with gentamicin MICs of up to 128 mg/L were selected. Primarily selected fusA mutations were further investigated, and fusAR635L and fusAM520I + R635L were particularly interesting. Different mutations in fusA and ubiM were found in low-level gentamicin-resistant mutants, while fusAM520I was associated with high-level gentamicin resistance. Protein structure predictions showed that fusAM520I is located in domain IV of the elongation factor-G (EF-G). The high-level gentamicin-resistant WHO X mutant was outcompeted by the gentamicin-susceptible WHO X parental strain, suggesting lower biofitness.


Conclusions
We describe the first high-level gentamicin-resistant gonococcal isolate (MIC = 128 mg/L), which was selected in vitro through experimental evolution. The most substantial increases of the gentamicin MICs were caused by mutations in fusA (G1560A and G1904T encoding EF-G M520I and R635L, respectively) and ubiM (D186N). The high-level gentamicin-resistant N. gonorrhoeae mutant showed impaired biofitness.
Topics

No keywords indexed for this article. Browse by subject →

References
62
[1]
WHO (2021)
[2]
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

Magnus Unemo, William M. Shafer

Clinical Microbiology Reviews 2014 10.1128/cmr.00010-14
[3]
Genomic evolution of Neisseria gonorrhoeae since the preantibiotic era (1928–2013): antimicrobial use/misuse selects for resistance and drives evolution

Daniel Golparian, Simon R. Harris, Leonor Sánchez-Busó et al.

BMC Genomics 2020 10.1186/s12864-020-6511-6
[4]
Gonorrhoea

Magnus Unemo, H Steven Seifert, Edward W. Hook et al.

Nature Reviews Disease Primers 2019 10.1038/s41572-019-0128-6
[5]
Unemo "2020 European guideline for the diagnosis and treatment of gonorrhoea in adults" Int J STD AIDS (2020) 10.1177/0956462420949126
[6]
WHO (2016)
[7]
Sexually Transmitted Infections Treatment Guidelines, 2021

Kimberly A. Workowski, Laura H. Bachmann, Philip A. Chan et al.

MMWR. Recommendations and Reports 2021 10.15585/mmwr.rr7004a1
[8]
Fifer "2018 UK national guideline for the management of infection with Neisseria gonorrhoeae" Int J STD AIDS (2020) 10.1177/0956462419886775
[9]
Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018

David W Eyre, Nicholas D Sanderson, Emily Lord et al.

Eurosurveillance 2018 10.2807/1560-7917.es.2018.23.27.1800323
[10]
Whiley "Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin" Lancet Infect Dis (2018) 10.1016/s1473-3099(18)30340-2
[11]
Pleininger "Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022" Euro Surveill (2022) 10.2807/1560-7917.es.2022.27.24.2200455
[12]
Nakayama "New ceftriaxone- and multidrug-resistant Neisseria gonorrhoeae strain with a novel mosaic penA gene isolated in Japan" Antimicrob Agents Chemother (2016) 10.1128/aac.00504-16
[13]
Lahra "Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain" Emerg Infect Dis (2018) 10.3201/eid2404.171873
[14]
Eyre "Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018" Euro Surveill (2019) 10.2807/1560-7917.es.2019.24.10.1900147
[15]
Day "Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022" Euro Surveill (2022) 10.2807/1560-7917.es.2022.27.46.2200803
[16]
Golparian "Multidrug-resistant Neisseria gonorrhoeae isolate, belonging to the internationally spreading Japanese FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, Ireland, August 2018" Euro Surveill (2018) 10.2807/1560-7917.es.2018.23.47.1800617
[17]
Clonal expansion and spread of the ceftriaxone-resistant Neisseria gonorrhoeae strain FC428, identified in Japan in 2015, and closely related isolates

Ken-Ichi Lee, Shu-Ichi Nakayama, Kayo Osawa et al.

Journal of Antimicrobial Chemotherapy 2019 10.1093/jac/dkz129
[18]
Trinh "Neisseria gonorrhoeae FC428 subclone, Vietnam, 2019–2020" Emerg Infect Dis (2022) 10.3201/eid2802.211788
[20]
Terkelsen "Multidrug-resistant Neisseria gonorrhoeae infection with ceftriaxone resistance and intermediate resistance to azithromycin, Denmark, 2017" Euro Surveill (2017) 10.2807/1560-7917.es.2017.22.42.17-00659
[21]
Berenger "Genetic characterization and enhanced surveillance of ceftriaxone-resistant Neisseria gonorrhoeae strain, Alberta, Canada, 2018" Emerg Infect Dis (2019) 10.3201/eid2509.190407
[22]
WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18: a retrospective observational study

Magnus Unemo, Monica M Lahra, Martina Escher et al.

The Lancet Microbe 2021 10.1016/s2666-5247(21)00171-3
[23]
Sánchez-Busó "Europe-wide expansion and eradication of multidrug-resistant Neisseria gonorrhoeae lineages: a genomic surveillance study" Lancet Microbe (2022) 10.1016/s2666-5247(22)00044-1
[24]
Gernert "Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance data" Lancet Microbe (2020) 10.1016/s2666-5247(20)30059-8
[25]
Lin "Markedly increasing antibiotic resistance and dual treatment of Neisseria gonorrhoeae isolates in Guangdong, China, from 2013 to 2020" Antimicrob Agents Chemother (2022) 10.1128/aac.02294-21
[26]
WHO
[27]
Kanj "Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections" Int J Antimicrob Agents (2022) 10.1016/j.ijantimicag.2022.106633
[28]
Brown "Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007" Sex Transm Dis (2010) 10.1097/olq.0b013e3181bf575c
[29]
Matoga "Gentamicin susceptibility in Neisseria gonorrhoeae and treatment outcomes for urogenital gonorrhea after 25 years of sustained gentamicin use in Malawi" Sex Transm Dis (2022) 10.1097/olq.0000000000001580
[30]
Chisholm "An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe" J Antimicrob Chemother (2011) 10.1093/jac/dkq476
[31]
Shaw "Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes" Microbiol Rev (1993) 10.1128/mr.57.1.138-163.1993
[32]
Mingeot-Leclercq "Aminoglycosides: activity and resistance" Antimicrob Agents Chemother (1999) 10.1128/aac.43.4.727
[33]
Ribosomal Resistance to Streptomycin and Spectinomycin in Neisseria gonorrhoeae

Michael J. Maness, Gayle C. Foster, P. Frederick Sparling

Journal of Bacteriology 1974 10.1128/jb.120.3.1293-1299.1974
[34]
Holley "A single amino acid substitution in elongation factor G can confer low-level gentamicin resistance in Neisseria gonorrhoeae" Antimicrob Agents Chemother (2022) 10.1128/aac.00251-22
[35]
Unemo "The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization" J Antimicrob Chemother (2016) 10.1093/jac/dkw288
[36]
Jacobsson "Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating Neisseria gonorrhoeae infections" Front Pharmacol (2022)
[37]
Berglund "One year of Neisseria gonorrhoeae isolates in Sweden: the prevalence study of antibiotic susceptibility shows relation to the geographic area of exposure" Int J STD AIDS (2002) 10.1258/0956462021924730
[38]
CLSI (2022)
[39]
Weinberg "Gradient agar plates" Am Biol Teach (1959) 10.2307/4439185
[40]
MEGA11: Molecular Evolutionary Genetics Analysis Version 11

Koichiro Tamura, Glen Stecher, Sudhir Kumar

Molecular Biology and Evolution 2021 10.1093/molbev/msab120
[41]
Argimón "Microreact: visualizing and sharing data for genomic epidemiology and phylogeography" Microb Genom (2016)
[43]
Jacobsson "Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model" Front Pharmacol (2022)
[44]
Vincent "In vivo-selected compensatory mutations restore the fitness cost of mosaic penA alleles that confer ceftriaxone resistance in Neisseria gonorrhoeae" mBio (2018) 10.1128/mbio.01905-17
[45]
Highly accurate protein structure prediction with AlphaFold

John Jumper, Richard Evans, Alexander Pritzel et al.

Nature 2021 10.1038/s41586-021-03819-2
[46]
Pfam: The protein families database in 2021

Jaina Mistry, Sara Chuguransky, Lowri Williams et al.

Nucleic Acids Research 2021 10.1093/nar/gkaa913
[47]
CASTp 3.0: computed atlas of surface topography of proteins

Wei Tian, Chang Chen, Xue Lei et al.

Nucleic Acids Research 2018 10.1093/nar/gky473
[48]
Whole-Genome Phylogenomic Heterogeneity of Neisseria gonorrhoeae Isolates with Decreased Cephalosporin Susceptibility Collected in Canada between 1989 and 2013

Walter Demczuk, Tarah Lynch, Irene Martin et al.

Journal of Clinical Microbiology 2015 10.1128/jcm.02589-14
[49]
Panecka "Interplay of the bacterial ribosomal A-site, S12 protein mutations and paromomycin binding: a molecular dynamics study" PLoS One (2014) 10.1371/journal.pone.0111811
[50]
Macé "The structure of an elongation factor G-ribosome complex captured in the absence of inhibitors" Nucleic Acids Res (2018) 10.1093/nar/gky081

Showing 50 of 62 references

Metrics
9
Citations
62
References
Details
Published
May 30, 2023
Vol/Issue
78(7)
Pages
1769-1778
License
View
Funding
NIH Award: AI47609
Department of Veterans Affairs
Örebro County Council Research Committee Award: AI47609
Cite This Article
Daniel Golparian, Susanne Jacobsson, Concerta L Holley, et al. (2023). High-level in vitro resistance to gentamicin acquired in a stepwise manner in Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy, 78(7), 1769-1778. https://doi.org/10.1093/jac/dkad168
Related

You May Also Like